PExA (PEXA) Q3 2024 earnings summary

Executive summary

• Net sales for Q3 2024 were 31,503 SEK, a sharp decline from 550,316 SEK in Q3 2023; nine-month sales totaled 251,201 SEK, down from 1,470,740 SEK year-over-year.

• Net loss after financial items for Q3 was -2,260,358 SEK (vs. -1,546,758 SEK); nine-month net loss was -7,210,668 SEK (vs. -5,758,413 SEK).

• Cash and cash equivalents at period end were 7,774,652 SEK, down from 12,059,687 SEK a year earlier.

• Solid equity ratio of 88.4% at period end, up from 86.0% last year.

Financial highlights

• Earnings per share for Q3 were -0.04 SEK (unchanged year-over-year); for nine months, -0.16 SEK (vs. -0.14 SEK).

• Operating loss for Q3 was -2,319,634 SEK (vs. -1,863,516 SEK); for nine months, -7,415,566 SEK (vs. -6,027,134 SEK).

• Cash flow from operations for nine months was -6,375,128 SEK (vs. -6,377,009 SEK); Q3 cash flow from operations was -2,718,676 SEK (vs. -2,259,961 SEK).

• Total assets at period end were 12,647,485 SEK, down from 18,043,130 SEK a year earlier.

Outlook and guidance

• Management continues to focus on expanding global presence, with technology now represented in Europe, USA, South Africa, and Australia.

• Ongoing efforts to transition from research to clinical diagnostic applications, aiming for broader market adoption.